Patients with previously untreated sAML were randomly assigned at a one-to-one ratio to cytarabine 200 mg/m ( 2 ) continuous intravenous ( IV ) infusion once per day on days 1 to 7 plus either amonafide 600 mg/m ( 2 ) IV over 4 hours on days 1 to 5 ( A + C arm ) or daunorubicin 45 mg/m ( 2 ) IV over 30 minutes once per day on days 1 to 3 ( D + C arm ) .